U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949396) titled 'Application of 18F-SSTR2 Antagonist PET/CT in Neuroendocrine Tumors' on Nov. 14.
Brief Summary: This study aims to evaluate the safety, distribution in normal organs, radiation dose, and diagnostic value of 18F-labeled somatostatin receptor subtype 2 (SSTR2) antagonist PET/CT imaging. Healthy volunteers will undergo imaging to assess tracer distribution and radiation exposure. Patients with pathologically confirmed grade 1 or 2 neuroendocrine tumors will undergo SSTR2 antagonist and 18F-octreotide PET/CT within 1 week to compare tumor detection and tracer uptake. Selected patients will also receive succinylated gelatin or amino acid...